Low Levels of Klothos Linked to Kidney Function Decline
|
By LabMedica International staff writers Posted on 15 Feb 2017 |

Image: The Dade Behring BN II automated nephelometer system (Photo courtesy of Siemens Healthcare).
The kidney has the highest levels of klotho expression and is likely the major source of soluble klotho and not surprisingly, therefore, levels of klotho tend to be low in patients with kidney disease.
Soluble klotho is a protein circulating in the blood that is thought to have anti-aging properties and although the exact mechanism of action of soluble klotho remains to be identified, the protein has been shown to influence multiple cellular and endocrine pathways.
A large team of scientists led by those at Tufts Medical Center carried out a prospective cohort initiated in 1997 with a goal of assessing how health conditions affect age-related physiologic and functional status. The study population consists of 3,075 persons aged 70 to 79 years at baseline with equal numbers of men and women and approximately one third African-Americans. All 2,496 participants who had measures of klotho and kidney function at baseline, and at least one repeat measure of kidney function were included in this study.
Serum soluble α-klotho was assayed using a commercially available sandwich enzyme-linked immunosorbent assay (ELISA) test from never-thawed frozen serum stored at -70 °C and obtained at the year two visit, approximately one year after the baseline visit. This assay is reported to have a sensitivity of 6.15 pg/mL, and demonstrated an interassay coefficient of 18%. The associations between soluble klotho levels and decline in kidney function and incident chronic kidney disease (CKD) were evaluated. Cystatin C was measured at baseline, as well as years three and 10, from stored frozen serum samples using a BNII nephelometer and an N Latex Cystatin C particle-enhanced immunonephelometric assay.
The scientists found that the median (25th, 75th percentiles) klotho level was 630 (477, 817) pg/mL. In fully adjusted models, each two-fold higher level of klotho associated with lower odds of decline in kidney function (odds ratio, 0.78) for 30% decline in estimated glomerular filtration rate (eGFR), and 0.85 for greater than 3 mL/min per year decline in eGFR, but not of incident CKD (incident rate ratio, 0.90). Overall, a higher soluble klotho level independently associated with a lower risk of decline in kidney function.
David A. Drew, MD, MS, the lead author of the study, said, “We found a strong association between low soluble klotho and decline in kidney function, independent of many known risk factors for kidney function decline. This suggests that klotho could play a role in the development of chronic kidney disease, although additional studies will need to confirm this. This also raises the possibility that klotho could be an important therapeutic target for future clinical trials.” The study was published on January 19, 2017, in the Journal of the American Society of Nephrology.
Soluble klotho is a protein circulating in the blood that is thought to have anti-aging properties and although the exact mechanism of action of soluble klotho remains to be identified, the protein has been shown to influence multiple cellular and endocrine pathways.
A large team of scientists led by those at Tufts Medical Center carried out a prospective cohort initiated in 1997 with a goal of assessing how health conditions affect age-related physiologic and functional status. The study population consists of 3,075 persons aged 70 to 79 years at baseline with equal numbers of men and women and approximately one third African-Americans. All 2,496 participants who had measures of klotho and kidney function at baseline, and at least one repeat measure of kidney function were included in this study.
Serum soluble α-klotho was assayed using a commercially available sandwich enzyme-linked immunosorbent assay (ELISA) test from never-thawed frozen serum stored at -70 °C and obtained at the year two visit, approximately one year after the baseline visit. This assay is reported to have a sensitivity of 6.15 pg/mL, and demonstrated an interassay coefficient of 18%. The associations between soluble klotho levels and decline in kidney function and incident chronic kidney disease (CKD) were evaluated. Cystatin C was measured at baseline, as well as years three and 10, from stored frozen serum samples using a BNII nephelometer and an N Latex Cystatin C particle-enhanced immunonephelometric assay.
The scientists found that the median (25th, 75th percentiles) klotho level was 630 (477, 817) pg/mL. In fully adjusted models, each two-fold higher level of klotho associated with lower odds of decline in kidney function (odds ratio, 0.78) for 30% decline in estimated glomerular filtration rate (eGFR), and 0.85 for greater than 3 mL/min per year decline in eGFR, but not of incident CKD (incident rate ratio, 0.90). Overall, a higher soluble klotho level independently associated with a lower risk of decline in kidney function.
David A. Drew, MD, MS, the lead author of the study, said, “We found a strong association between low soluble klotho and decline in kidney function, independent of many known risk factors for kidney function decline. This suggests that klotho could play a role in the development of chronic kidney disease, although additional studies will need to confirm this. This also raises the possibility that klotho could be an important therapeutic target for future clinical trials.” The study was published on January 19, 2017, in the Journal of the American Society of Nephrology.
Latest Clinical Chem. News
- Saliva-Based Test Detects Biochemical Signs of Sleep Loss
- Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
- Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
- Urine-Based Test Shows Promise for Autism Screening in Children
- Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
- Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
- Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation
- Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma
- New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
- Blood-Based Biomarkers Show Promise for Psychosis Risk Prediction
- International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
- Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
- Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
- FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
- CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
- Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Channels
Molecular Diagnostics
view channel
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read more
Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
Adjuvant therapy decisions after curative surgery for colon cancer remain difficult, as conventional clinicopathologic factors often fail to capture residual disease risk. Liquid biopsy approaches that... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read more
FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
Clinical laboratories play a central role in guiding immunotherapy by reporting programmed death ligand-1 (PD‑L1) status across multiple solid tumors. Many sites are standardizing this work on fully automated... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








